Raymond James Initiates Coverage On Avalyn Pharma with Outperform Rating, Announces Price Target of $60

Raymond James analyst Tiago Fauth has initiated coverage on Avalyn Pharma (NASDAQ: AVLN) with an Outperform rating. The firm has set a price target of $60 for the company's stock.